FASTHEADLINENEWS

$VRDN Headlines

8 trading headlines for $VRDN

Apr 2 12:38 PM

Evercore ISI Group Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $32

analystAlpaca

Mar 31 04:41 PM

Goldman Sachs Maintains Buy on Viridian Therapeutics, Lowers Price Target to $36

analystAlpaca

Mar 31 02:09 PM

Wedbush Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $37

analystAlpaca

Mar 31 01:48 PM

Wells Fargo Maintains Equal-Weight on Viridian Therapeutics, Lowers Price Target to $20

analystAlpaca

Mar 31 11:09 AM

HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $22

analystAlpaca

Mar 30 05:48 PM

Needham Maintains Buy on Viridian Therapeutics, Lowers Price Target to $32

analystAlpaca

Mar 30 01:16 PM

UPDATE: Viridian Therapeutics' REVEAL-1 Study Shows Elegrobart Efficacy; Q4W CAS And Q8W Diplopia Endpoints Miss Statistical Significance; Shares Trading Lower, Future Trial Dependence May Concern Investors

fdaAlpaca

Mar 30 11:16 AM

Viridian Therapeutics Says REVEAL-1 Study Met Primary Endpoint Of Every Four Weeks (Q4W) Proptosis Responder Rate In Thyroid Eye Disease

generalAlpaca